Molecular docking studies of novel thiazolidinedione analogs as HIV-1-RT inhibitors

Medicinal Chemistry Research

Volumn 22, Issue 7, 2013, Pages 3350-3363

  Ganguly, Swastika ^a   Bahare, Radhe Shyam ^a  

^a BIRLA INSTITUTE OF TECHNOLOGY   (India)

Author keywords

Docking; HIV; NNRTIs; Reverse transcriptase; Thiazolidinediones

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; AMINO ACID; RNA DIRECTED DNA POLYMERASE;

ARTICLE; BINDING AFFINITY; CONFORMATION; ENZYME ACTIVE SITE; MOLECULAR DOCKING; MOLECULAR INTERACTION; X RAY CRYSTALLOGRAPHY;

EID: 84878825109     PISSN: 10542523     EISSN: 15548120     Source Type: Journal    
DOI: 10.1007/s00044-012-0339-9     Document Type: Article

References (28)

1. Bal TR, Anand B, Yogeeswari P, Sriram D (2005) Synthesis and evaluation of anti-HIV activity of isatin beta- thiosemicarbazone derivatives. Bioorg Med Chem Lett 15:4451
2. Barreca ML, Balzarini J, Chimirri A, De Clercq E, Luca LD, Holtje MH, Holtje M, Monforte AM, Monforte P, Pannecouque C, Rao A, Zappala M (2002) Discovery of 2,3-diaryl-1,3-thiazolidin-4-ones as potent anti-HIV-1 agents. J Med Chem 45:5410-5413
3. Bell FW, Cantrell AS, Hoegberg M, Jaskunas SR, Johansson NG, Jordan CL, Kinnick MD, Lind P, Morin JM (1995) Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. Synthesis and basic structure-activity relationship studies of PETT analogs. J Med Chem 38:4929-4936
4. Das K, Lewi PJ, Hughes SH, Arnold E (2005) Crystallography and the design of anti AIDS drugs conformational flexibility and positional adaptability are important in design of non nucleoside HIV-1- reverse transcriptase inhibitors. Prog Biophys Mol Biol 88:209-231
5. Dundar OB, Ozgen O, Mentese A, Altanlar N, Ath O, Kendi E, Ertan R (2007) Synthesis and antimicrobial activity of some new thiazolyl thiazolidine-2,4- dione derivatives. Bioorg Med Chem 15:6012-6017
6. FlexX 1.0 (2010) BioSolveIT GmbH. An der Ziegele, St. Augustin
7. Freitas RF, Galembeck SE (2006) Computational study of the interaction between TIBO inhibitors and Y181 (C181), K101, and Y188 amino acids. J Phys Chem 110:21287-21298
8. Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, Repasky MP, Knoll EH, Shelley M, Perry JK, Shaw DE, Francis P, Shenkin PS (2004) Glide: a new approach for rapid, accurate docking and scoring: 1. Method and assessment of docking accuracy. J Med Chem 47:1739-1749
9. Heerding DA, Christmann LT, Clark TJ, Holmes DJ, Rittenhouse ST, Takata DT, Venslavsky JW (2003) New benzylidenethiazolidinediones as antibacterial agents. Bioorg Med Chem Lett 13:377-3771
10. Hopkins AL, Ren J, Esnouf RM, Willcox BE, Jones EY, Ross C, Miyasaka T, Walker RT, Tanaka H, Stammers DK, Stuart DI (1996) Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT Series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors. J Med Chem 39:1589-1600
11. http://poseview.zbh.uni-hamburg.de/poseview. Accessed 22 Mar 2012
12. http://www.rcsb.org/pdb. Accessed 22 Mar 2012
13. Huang H, Chopra R, Verdine GL, Harrison SC (1998) Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science 282:1669-1675
14. Kohlstaedt LA, Wang J, Friedman JM, Rice PA, Steitz TA (1992) Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 256:1783-1790
15. Koska J, Spassov VZ, Maynard AJ, Yan L, Austin N, Flook PK, Venkatachalam CM (2008) Fully automated molecular mechanics based induced fit protein-ligand docking method. J Chem Inf Model 48:1965-1973
16. Krovat EM, Steindl T, Langer T (2005) Recent advances in docking and scoring. Curr Comput Aided Drug Des 1:102-193
17. Malik S, Choudhary A, Bahare RS (2011) Synthesis of some novel substituted arylidene and substituted benzylthiazolidine-2,4-dione analogues as chemotherapeutic agents. Asian J Chem 23:5547-5548
18. Muegge I, Martin Y (1999) A general and fast scoring function for protein-ligand interactions: a simplified potential approach. J Med Chem 42:791-804
19. Patil V, Kalpana T, Sonali MM, Rhea M, Ramaa CS (2010) Synthesis and primary cytotoxicity evaluation of new 5-benzylidene-2,4-thiazolidinedione derivatives. Eur J Med Chem 45:4539-4544
20. Ragno R, Frasca S, Manetti F, Brizzi A, Massa S (2005) HIV-reverse transcriptase inhibition: inclusion of ligand-induced fit by cross-docking studies. J Med Chem 48:200-212
21. Schafer W, Friebe WG, Leinert M, Merttens A, Poll T, Von der Saal W, Zilch H, Nuber H, Ziegler ML (1993) Non-nucleoside inhibitors of HIV-1 reverse transcriptase: molecular modeling and X-ray structure investigations. J Med Chem 36:726-732
22. Schrodinger Inc. (2008) USA, Schrodinger, LLC, New York
23. Scigress Explorer Ultra 7.7 (2008) Fujitsu Limited, Poland
24. Shohda T, Mizuno K, Tawada H, Sugiyama Y, Fugita T, Kawamatsu Y (1982) Novel euglycemic and hypolipidemic agents: part-2 antioxidant moiety as structural motif. Chem Pharm Bull 30:3563
25. Sriram D, Bal TR, Perumal Y (2004) Design, synthesis and biological evaluation of novel non-nucleoside HIV-1 reverse transcriptase inhibitors with broad-spectrum chemotherapeutic properties. Bioorg Med Chem 12:5865-5873
26. Tuncbilek M, Altanlar N (2006) Synthesis of new 3-(substituted phenacyl)-5-[3′-(4H-4-oxo-1-benzopyran-2-yl)-benzylidene]-2, 4-thiazolidinediones and their antimicrobial activity. Arch Pharm (Weinheim) 339:213-216
27. William LJ, David SM, Julian T (1996) Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids. J Am Chem Soc 118:11225-11236
28. Yusuf D, Davis AM, Kleywegt GJ, Schmitt S (2008) An alternative method for the evaluation of docking performance: RSR vs RMSD. J Chem Inf Model 48:1411-1422